Drug General Information (ID: DDI9SZMDOA)
Drug Name			Ketoprofen		Drug Info		Pralatrexate		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Analgesics				Antimetabolites
Structure

Mechanism of Ketoprofen-Pralatrexate Interaction (Severity Level: Moderate)
Competitive inhibition of renal tubular secretion Click to Show/Hide Mechanism Graph
Drug Name		Ketoprofen				Pralatrexate
Mechanism		Competitive inhibition of renal tubular secretion of pemetrexed				Pralatrexate
Key Mechanism Factor 1
		Factor Name		Renal tubular secretion
		Factor Description		Renal tubular secretion allows selective transfer of substances from the blood around the capillaries into the renal tubules via filtrate. Drug excretion may be reduced when two drugs compete for renal tubular secretion.
Mechanism Description		Decreased elimination of Ketoprofen caused by Pralatrexate mediated competitive inhibition of renal tubular secretion

Recommended Action
Management		Caution is advised if pralatrexate is prescribed in combination with trimethoprim/sulfamethoxazole or NSAIDs. Complete blood cell counts as well as renal and hepatic function should be closely monitored. Treatment interruption or dose reduction of pralatrexate may be required if toxicities such as mucositis, myelosuppression, or liver enzyme abnormalities develop. Patients should be advised to contact their physician if they develop oral ulcers, painful swallowing, vomiting, diarrhea, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.

References
1	Product Information. Folotyn (pralatrexate). Allos Therapeutics, Westminster, CO.